U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06795048) titled 'A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration' on Jan. 24.
Brief Summary: This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naive in the study eye.
Study Start Date: Feb. 14
Study Type: INTERVENTIONAL
Condition:
Neovascular Age-related Macular Degeneration (nAMD)
Intervention:
DRUG: Faricim...